Inactive Instrument

Abiomed, Inc.

Equities

ABMD

US0036541003

Advanced Medical Equipment & Technology

Abiomed, Inc. Announces Revenue Guidance for the Fiscal Year of 2021

January 28, 2021 at 07:00 am EST

Abiomed, Inc. announced revenue guidance for the fiscal year of 2021. For the year, the company anticipated global revenue to be in the range of $225 million to $235 million, representing 9% to 14% growth compared to fourth quarter fiscal year 2020.

Latest news about Abiomed, Inc.

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium	23-10-23	CI
ABIOMED, Inc. Announces Termination of Todd A. Trapp as Chief Financial Officer	22-12-22	CI
ABIOMED, Inc. Announces Management Changes	22-12-22	CI
ABIOMED, Inc. Announces Termination of Michael R. Minogue as Chief Executive Officer	22-12-22	CI
Johnson & Johnson Closes Acquisition of Abiomed	22-12-22	MT
Abiomed, Inc.(NasdaqGS:ABMD) dropped from NASDAQ Composite Index	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Global 1200	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Healthcare Equipment Select Industry Index	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equipment & Services (Industry Group)	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equipment & Supplies	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Composite 1500	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Health Care Equipment (Sub Ind)	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Growth	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P 500 Equal Weighted	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P TMI Index	22-12-22	CI
Abiomed, Inc.(NasdaqGS:ABMD) dropped from S&P Global BMI Index	22-12-22	CI
Johnson & Johnson completed the acquisition of Abiomed, Inc..	22-12-21	CI
Abiomed Says US FDA Approves Impella ECP Pivotal Heart Pump	22-12-21	MT
Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP	22-12-21	CI
Steel Dynamics to Join S&P 500; Super Micro Computer to be Added to S&P MidCap 400	22-12-20	MT
Johnson & Johnson Extends Abiomed Tender Offer to Dec. 21	22-12-14	MT
Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index	22-12-14	CI

Chart Abiomed, Inc.

Duration

Period

More charts

Company Profile

Abiomed, Inc. specializes in the development, manufacturing and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows: - sale of products (95.4%): heart pumps (Impella brand); - sale of services (4.6%): including preventive maintenance services. Net sales are distributed geographically as follows: the United States (81.2%), Europe (12.8%), Japan (5%) and other (1%).

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+11.18%	225B
DANAHER CORPORATION	+15.22%	197B
INTUITIVE SURGICAL, INC.	+19.19%	143B
BOSTON SCIENTIFIC CORPORATION	+30.89%	111B
SIEMENS HEALTHINEERS AG	+1.86%	64.72B
EDWARDS LIFESCIENCES CORPORATION	+18.48%	54.44B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.12%	51.06B
AGILENT TECHNOLOGIES, INC.	+10.53%	45.03B
GE HEALTHCARE TECHNOLOGIES INC.	+5.98%	37.4B

Other Advanced Medical Equipment & Technology